石药集团宣布,其自主研发的SYH2082注射液——一种GLP-1/GIP受体双偏向激动剂多肽长效制剂,正式获得中国国家药品监督管理局的临床试验许可。该创新药物针对代谢性疾病治疗领域,通过双重作用机制实现更优疗效,标志着企业在代谢类创新药研发取得重要突破。
石药集团宣布,其自主研发的SYH2082注射液——一种GLP-1/GIP受体双偏向激动剂多肽长效制剂,正式获得中国国家药品监督管理局的临床试验许可。该创新药物针对代谢性疾病治疗领域,通过双重作用机制实现更优疗效,标志着企业在代谢类创新药研发取得重要突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.